selected publications
-
academic article
- Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial.. Circulation research. 135:575-592. 2024
- Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial. Cancer Prevention Research. 2023
- Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data. Quality of Life Research. 2023
- Risk factors for long-term adjuvant chemotherapy toxicity using pre-treatment host factors and self-rated treatment bother (GP5) in a clinical trial population. Cancer Research. 2022
- Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30. npj Breast Cancer. 2022
- Using body temperature and variables commonly available in the EHR to predict acute infection: a proof-of-concept study showing improved pretest probability estimates for acute COVID-19 infection among discharged emergency department patients.. Diagnosis (Berlin, Germany). 8:450-457. 2021
- Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. Journal of Clinical Oncology. 2021
- Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. JNCI: Journal of the National Cancer Institute. 2020
- Measuring the tolerability of cancer therapy: incorporating host factors as moderators of toxicity and outcomes. Quality of Life Research. 2020
-
document
- Data from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial 2023
- Supplementary Figure S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial 2023
- Supplementary Methods S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial 2023
- Supplementary Table S1 from Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial 2023